EPO and Parkinson disease: As support to the introduction of this new formulation of the rhEPO studies were shown in fimbria-fornix injury models in rats, in naturally aged macaques with cognitive deterioration and in a PD clinical trial as shown by the Ciren, Cetex and Cenpalab specialists, showing good tolerance and effects positive in some cognitive functions, sustaining the assumption that EPO can act not only as a neuroprotective substance, but is also able to modulate transient neural plasticity mechanisms and therefore to promote the recovery of nerve function after an established chronic brain lesion.